LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

CheckMate 078: Patient‐Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non‐Small Cell Lung Cancer (NSCLC): OA10

Photo by impulsq from unsplash

Conclusion: We interrogated the characteristics of ERBB2 exon 20 insertions in a large cohort from single ethnicity. It demonstrated the response heterogeneity to afatinib among different ERBB2 exon 20 insertion… Click to show full abstract

Conclusion: We interrogated the characteristics of ERBB2 exon 20 insertions in a large cohort from single ethnicity. It demonstrated the response heterogeneity to afatinib among different ERBB2 exon 20 insertion subtypes. It highlighted the importance to correlate drug efficacy with specific ERBB2 exon 20 insertion variants in clinical application.

Keywords: reported outcomes; checkmate 078; outcomes pros; 078 patient; erbb2 exon; patient reported

Journal Title: Journal of Thoracic Oncology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.